Supplementary Table 2. Clinical characteristics at baseline and 48-week clinical outcomes of TAF compared to TDF in the propensity score-matched cohort

Characteristic	TAF (n=70)	TDF (n=140)	*P*-value
SBP (mmHg)	121.8±10.8	122.8±12.5	0.711
Fatty liver disease (%)	12 (17.1)	37 (26.4)	0.867
Platelet (1,000/mm^3)	179.0±64.2	188.4±58.9	0.213
Albumin (g/dL)	4.3±0.4	4.4±0.4	0.082
Bilirubin (mg/dL)	0.9±0.6	1.0±1.0	0.616
PT (INR)	1.0±0.1	1.2±0.4	0.168
AST (U/mL)	84.5±124.2	95.6±211.6	0.636
ALT (U/mL)	128.9±212.4	146.8±381.2	0.669
AFP (ng/dL)	9.2±28.1	9.7±30.2	0.887
HBeAg positivity (%)	46 (65.7)	88 (62.9)	0.617
Clinical outcome			
Serum Cr. at 48 weeks (mg/dL)	0.9±0.2	0.9±0.2	0.284
ALT normalization (%)	57 (81.4)	101 (72.1)	0.194
VR 12 (%)	66 (94.3)	123 (87.9)	0.223

Values are presented as mean±standard deviation or number (%).
TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; SBP, systolic blood pressure; PT, prothrombin time; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; HBeAg, hepatitis B e antigen; Cr., creatinine; VR12, virologic response at 12 months.